Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.

PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages Read More

2024-03-25T09:03:49-04:00July 2nd, 2017|Adjuvant, Evidence, MammaPrint, MINDACT|

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS:  Peter Read More

2024-03-25T09:14:21-04:00April 26th, 2017|BluePrint, Evidence, NBRST, Neoadjuvant|

DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial

PUBLICATION: NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. AUTHORS: Read More

2024-02-22T12:01:50-05:00March 1st, 2017|Evidence, I-SPY2, Neoadjuvant|

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue Read More

2024-03-25T09:16:48-04:00October 21st, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Genomic Profiling of Breast Cancer in African-American Women Using MammaPrint.

PUBLICATION: Breast Cancer Res Treat (2016) 159: 481. https://doi.org/10.1007/s10549-016-3949-y09. AUTHORS: Read More

2024-03-25T09:17:41-04:00August 27th, 2016|Evidence, MammaPrint, Other, Racial Disparities|

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Read More

2024-03-25T09:19:31-04:00July 6th, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|
Go to Top